---
document_datetime: 2025-01-13 17:12:36
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/skyclarys-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: skyclarys-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.2903537
conversion_datetime: 2025-12-18 10:18:34.936019
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Skyclarys

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                       |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------|
| II/0010              | Update of section 4.8 of the SmPC in order to add hypersensitivity, including urticaria and rash, to the list of adverse drug reactions (ADRs) with frequency not known based on post-marketing experience. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce | 12/12/2024                          |                                             | SmPC and PL                      | For more information, please refer to the Summary of Product Characteristics. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | corrections and minor changes to the PI and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     |      |                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------|
| IB/0014           | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                 | 21/10/2024 | n/a |      |                                   |
| PSUSA/245/2 02402 | Periodic Safety Update EU Single assessment - omaveloxolone                                                                                                                                                                         | 03/10/2024 | n/a |      | PRAC Recommendation - maintenance |
| IA/0013           | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                        | 19/09/2024 | n/a |      |                                   |
| II/0009           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                   | 12/09/2024 |     | SmPC |                                   |
| II/0008           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                   | 12/09/2024 |     | SmPC |                                   |
| IB/0011           | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                             | 05/09/2024 | n/a |      |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0012/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                                 | 20/08/2024   | n/a        |                        | changes to an approved test   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------|
| T/0007      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                  | 08/07/2024   | 05/08/2024 | SmPC, Labelling and PL |                               |
| II/0004     | B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP                                                                                                                                                       | 11/07/2024   | n/a        |                        |                               |
| II/0003/G   | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting | 13/06/2024   | n/a        |                        |                               |

<div style=\"page-break-after: always\"></div>

|             | replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different   |            |            |                 |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0006/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer                                                                                                                                                                                                                                                                                                                                                                                          | 05/06/2024 | 05/08/2024 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

|           | Not including batch control/testing                                                                                                                                                                                  |            |            |                 |                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------|
| IA/0002   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where takes place | 05/04/2024 | n/a        |                 | batch control/testing |
| IAIN/0001 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - control/testing   | 07/03/2024 | 05/08/2024 | Annex II and PL | Not including batch   |